1 citations
,
June 2022 in “JAMA” This study found that oral baricitinib treatment led to hair regrowth in patients with alopecia areata, as observed in two phase 3 trials.
In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.
November 2025 in “Turkish Journal of Dermatology” In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.
5 citations
,
May 2025 in “Journal of the American Academy of Dermatology”
September 2023 in “JAAD case reports” In this review, the authors noted that while baricitinib, a treatment for refractory rheumatoid arthritis and severe alopecia areata, shows promising efficacy, it may pose risks of serious infections and malignancy due to immune downregulation.